NCT04075955 - Feasibility of Olanzapine at REduced doSe in hIGHly Emetogenic chemoTherapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 29, 2019

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions

Chemotherapy-induced Nausea and Vomiting

Interventions

DRUG

Zyprexa® (OLANZapine 5MG)

"Olanzapine 5mg orally at bedtime for 4 days (starting the day before the chemotherapy)~Ondansetron 16mg orally pre-chemotherapy on day 1~Dexamethasone 12mg orally pre-chemotherapy on day 1~Dexamethasone 8mg orally twice a day for 6 doses (starting on the morning of day 2)"

DRUG

Emend® (Aprepitant)

"Aprepitant 125mg orally pre-chemotherapy on day 1, then 80mg orally once daily on days 2 and 3~Ondansetron 16mg orally pre-chemotherapy on day 1~Dexamethasone 12mg orally pre-chemotherapy on day 1~Dexamethasone 8mg orally once daily for 3 doses (starting on the morning of day 2)"

Trial Locations (1)

J4V2H1

Hôpital Charles-LeMoyne, Greenfield Park

All Listed Sponsors

lead

CR-CSSS Champlain-Charles-Le Moyne

OTHER